Cargando…

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yetmar, Zachary A, Khodadadi, Ryan B, Seville, Maria Teresa, Brumble, Lisa, O’Horo, John C, Ganesh, Ravindra, Razonable, Raymund R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047222/ https://www.ncbi.nlm.nih.gov/pubmed/35791358 http://dx.doi.org/10.1093/ofid/ofac204

Ejemplares similares

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
por: Thilagar, Bright P., et al.
Publicado: (2022)

Factors Associated with Infectious Diseases Fellowship Academic Success
por: Khodadadi, Ryan B., et al.
Publicado: (2023)

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
por: Chatterjee, Suparna, et al.
Publicado: (2022)

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?
por: Cano, Edison J, et al.
Publicado: (2020)

1691. Cryptococcus Species Other than C. neoformans and C. gattii: Are They Clinically Significant?
por: Cano Cevallos, Edison J, et al.
Publicado: (2019)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Guide to Understanding the 2019 Novel Coronavirus
por: Shah, Aditya, et al.
Publicado: (2020)

2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
por: Yetmar, Zachary, et al.
Publicado: (2018)

290. Hepatitis E Virus Serostatus: A Retrospective Assessment of Demographics and Comorbidities to Assess High-risk Populations
por: Stone, Eric C, et al.
Publicado: (2019)

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Dhand, Abhay, et al.
Publicado: (2022)

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019
por: Anderson, Blake, et al.
Publicado: (2021)

Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID-19 Disease
por: Yelle, Sangeeta, et al.
Publicado: (2023)

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
por: Kasten, Mary J., et al.
Publicado: (2023)

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
por: Ordaya, Eloy E, et al.
Publicado: (2022)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2020)

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
por: Gharbharan, Arvind, et al.
Publicado: (2021)

Mortality After Nocardiosis: Risk Factors and Evaluation of Disseminated Infection
por: Yetmar, Zachary A, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Digital Health Surveillance Strategies for Management of Coronavirus Disease 2019
por: Jose, Thulasee, et al.
Publicado: (2020)

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
por: Ambrose, Nalini, et al.
Publicado: (2023)

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19
por: Bierle, Dennis M., et al.
Publicado: (2021)

2692. Epidemiology and Risk Factors for Clostridioides difficile Infection after Pancreas Transplantation
por: Akhtar, Haris, et al.
Publicado: (2023)

2884. Incidence of Invasive Fungal Infections After Pancreas Transplantation
por: Nair, Vaisak, et al.
Publicado: (2023)

Babesiosis: A Retrospective Review of 38 Cases in the Upper Midwest
por: Fida, Madiha, et al.
Publicado: (2019)

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis
por: Cano, Edison J., et al.
Publicado: (2021)

An Unusual Cluster of Neuroinvasive Lyme Disease Cases Presenting With Bannwarth Syndrome in the Midwest United States
por: Shah, Aditya, et al.
Publicado: (2017)

Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19
por: Yetmar, Zachary A., et al.
Publicado: (2021)

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
por: Zendt, Mackenzie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bnrfvfsgfave3dbrmpp73juk3l